Drug Search Results
More Filters [+]

PF-04995274

Alternative Names: pf-04995274
Latest Update: 2022-11-04
Latest Update Note: Clinical Trial Update

Product Description

Pfizer is developing PF-04995274 as a treatment for Unipolar Depression. (Sourced from: https://clinicaltrials.gov/study/NCT03516604)

Mechanisms of Action: 5-HT4 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PF-04995274

Countries in Clinic: United Kingdom

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Depressive Disorder

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

RESTAND

P1

Completed

Depressive Disorder

2022-07-29

Recent News Events

Date

Type

Title